Related Experiment Video
Updated: Jun 10, 2026
Application of CRISPR Interference (CRISPRi) for Gene Silencing in Pathogenic Species of Leptospira
Published on: August 14, 2021
CRISPR-based gene editing for antimicrobial resistance control in human medicine
Abdullah Afzal Alvi1, Muzzamil Hussain2, Sadia Noureen2
1Department of Plant Production & Biotechnology, Faculty of Agricultural Sciences and Technology (FAST), University of Layyah, Layyah, 31200, Pakistan. abdullahafzalalvibiotec@gmail.com.
Abstract:
Antimicrobial resistance (AMR) has already become one of the most urgent threats to the public health of this century. In 2019 alone, it directly causes about 1.27 million deaths and it was estimated that 1.91 million people will die yearly by 2050 should present trends persist. The traditional antibiotic development pipelines have been shown to be structurally insufficient to meet the rate at which bacterial populations have developed, diversified and spread resistance determinants, typically by horizontal gene transfer. In this context, CRISPR-Cas gene editing has become a focused antimicrobial approach that can selectively target resistance genes, virulence factors, and mobile genetic elements without the broad-spectrum collateral damage associated with conventional antibiotics. The review assesses CRISPR-Cas systems, namely Cas9, Cas12a, Cas3, and Cas13 in the context of two complementary mechanistic strategies namely selective killing of pathogens and antibiotic resensitization by the targeted disruption of gene resistance. We compare the impact of key delivery systems, such as bacteriophage vectors, lipid nanoparticles, and conjugative plasmids, evaluating them based on their therapeutic activity, host selectivity, and possible translation. The present state of clinical translations is discussed, including the two most advanced clinical-stage candidates SNIPR001 (Phase I/II, NCT05277350) and LBP-EC01 (Phase 2/3, NCT05488444). We also address the open issues that include off-target editing, host immune reactions, bacterial counter-resistance, regulatory ambiguity, and scalability of manufacturing. Lastly, we provide priority research directions, such as the combination antimicrobial strategies, AI-assisted CRISPR design, and next-generation delivery engineering, none of which will be resolved before routine clinical application of CRISPR-based antimicrobials is achieved.
Insights
CRISPR-Cas gene editing offers a novel approach to combat antimicrobial resistance (AMR) by selectively targeting harmful bacteria and restoring antibiotic effectiveness. This technology shows promise in overcoming the limitations of traditional antibiotics and addressing the growing global health threat of AMR.
Area of Science:
- Microbiology
- Biotechnology
- Genetics
Background:
- Antimicrobial resistance (AMR) is a critical global health threat, causing millions of deaths annually and challenging conventional treatments.
- Traditional antibiotic development struggles to keep pace with bacterial evolution and spread of resistance mechanisms.
- CRISPR-Cas gene editing presents a targeted alternative to broad-spectrum antibiotics, capable of selectively eliminating pathogens or disabling resistance genes.
Purpose of the Study:
- To review CRISPR-Cas gene editing systems (Cas9, Cas12a, Cas3, Cas13) as antimicrobial strategies.
- To evaluate delivery systems like bacteriophages, lipid nanoparticles, and plasmids for CRISPR-based antimicrobials.
- To discuss the clinical translation, challenges, and future research directions for CRISPR-based AMR solutions.
Main Methods:
- Assessment of CRISPR-Cas systems (Cas9, Cas12a, Cas3, Cas13) for selective pathogen killing and antibiotic resensitization.
- Comparison of bacteriophage vectors, lipid nanoparticles, and conjugative plasmids as delivery mechanisms.
- Review of current clinical trials (SNIPR001, LBP-EC01) and identification of challenges and future research priorities.
Main Results:
- CRISPR-Cas systems can be engineered to target resistance genes, virulence factors, and mobile genetic elements.
- Various delivery systems show potential for therapeutic activity and host selectivity, though translation varies.
- Clinical trials are underway, indicating progress in translating CRISPR-based antimicrobials into therapeutic applications.
Conclusions:
- CRISPR-Cas gene editing holds significant promise for combating AMR through targeted mechanisms.
- Further research is needed to address challenges such as off-target effects, immune responses, bacterial counter-resistance, and manufacturing scalability.
- Future directions include combination therapies, AI-driven design, and advanced delivery systems to achieve routine clinical application.
Related Concept Videos
01:28CRISPR/Cas9 Genome Editing
01:59CRISPR
01:59CRISPR
00:49What is Genetic Engineering?
02:53CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
00:57Antibiotic Selection